TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET: GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 DBMR MARKET POSITION GRID
2.7 DBMR VENDOR SHARE ANALYSIS
2.8 MULTIVARIATE MODELING
2.9 PRODUCTS LIFELINE CURVE
2.10 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.1.1 INVESTMENT IN R&D ACTIVITIES BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
3.1.2 RISING NUMBER OF DISEASES
3.1.3 GROWING GOVERNMENT INITIATIVES
3.2 RESTRAINTS
3.2.1 HIGH COST OF INSTRUMENTS
3.2.2 STRINGENT GOVERNMENT REGULATIONS
3.3 OPPORTUNITIES
3.3.1 AVAILIBILITY OF NUMBER OF TECHNIQUES FOR DETECTION OF MYCOPLASMA
3.3.2 STRATEGIC INITIATIVES BY VARIOUS COMPANIES
3.4 CHALLENGES
3.4.1 LACK OF SKILLED PROFESSIONALS
3.4.2 CHALLENEGES IN THE DIAGNOSIS OF MYCOPLASMA INFECTION
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
6 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS
6.1 OVERVIEW
6.2 KITS & REAGENTS
6.3 INSTRUMENTS
6.4 SERVICES
7 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUES
7.1 OVERVIEW
7.2 MICROBIAL CULTURE TECHNIQUES/DIRECT ASSAY
7.3 POLYMERASE CHAIN REACTION
7.4 ELISA
7.5 DNA STAINING/INDIRECT ASSAY
7.6 ENZYMATIC METHODS
7.7 OTHERS
8 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA
8.1 OVERVIEW
8.2 RESPIRATORY
8.2.1 BY CAUSATIVE AGENT
8.2.1.1 MYCOPLASMA PNEUMONIAE
8.2.1.2 MYCOPLASMA HOMINIS
8.2.1.3 UREAPLASMA UREALYTICUM
8.2.1.4 MYCOPLASMA GENITALIUM
8.2.1.5 OTHERS
8.2.2 BY TECHNIQUE
8.2.2.1 MICROBIAL CULTURE TECHNIQUES/DIRECT ASSAY
8.2.2.2 POLYMERASE CHAIN REACTION
8.2.2.3 ELISA
8.2.2.4 DNA STAINING/INDIRECT ASSAY
8.2.2.5 ENZYMATIC METHODS
8.2.2.6 OTHERS
8.3 UROGENITAL
8.3.1 BY CAUSATIVE AGENT
8.3.1.1 MYCOPLASMA HOMINIS
8.3.1.2 UREAPLASMA UREALYTICUM
8.3.1.3 MYCOPLASMA GENITALIUM
8.3.1.4 MYCOPLASMA PNEUMONIAE
8.3.1.5 OTHERS
8.3.2 BY TECHNIQUE
8.3.2.1 MICROBIAL CULTURE TECHNIQUES/DIRECT ASSAY
8.3.2.2 POLYMERASE CHAIN REACTION
8.3.2.3 ELISA
8.3.2.4 DNA STAINING/INDIRECT ASSAY
8.3.2.5 ENZYMATIC METHODS
8.3.2.6 OTHERS
8.4 GASTROINTESTINAL
8.4.1 BY CAUSATIVE AGENT
8.4.1.1 MYCOPLASMA PNEUMONIAE
8.4.1.2 MYCOPLASMA HOMINIS
8.4.1.3 UREAPLASMA UREALYTICUM
8.4.1.4 MYCOPLASMA GENITALIUM
8.4.1.5 OTHERS
8.4.2 BY TECHNIQUE
8.4.2.1 MICROBIAL CULTURE TECHNIQUES/DIRECT ASSAY
8.4.2.2 POLYMERASE CHAIN REACTION
8.4.2.3 ELISA
8.4.2.4 DNA STAINING/INDIRECT ASSAY
8.4.2.5 ENZYMATIC METHODS
8.4.2.6 OTHERS
8.5 CARDIOVASCULAR
8.5.1 BY CAUSATIVE AGENT
8.5.1.1 MYCOPLASMA PNEUMONIAE
8.5.1.2 MYCOPLASMA HOMINIS
8.5.1.3 UREAPLASMA UREALYTICUM
8.5.1.4 MYCOPLASMA GENITALIUM
8.5.1.5 OTHERS
8.5.2 BY TECHNIQUE
8.5.2.1 MICROBIAL CULTURE TECHNIQUES/DIRECT ASSAY
8.5.2.2 POLYMERASE CHAIN REACTION
8.5.2.3 ELISA
8.5.2.4 DNA STAINING/INDIRECT ASSAY
8.5.2.5 ENZYMATIC METHODS
8.5.2.6 OTHERS
?
8.6 MUSCULOSKELETAL
8.6.1 BY CAUSATIVE AGENT
8.6.1.1 MYCOPLASMA PNEUMONIAE
8.6.1.2 MYCOPLASMA HOMINIS
8.6.1.3 UREAPLASMA UREALYTICUM
8.6.1.4 MYCOPLASMA GENITALIUM
8.6.1.5 OTHERS
8.6.2 BY TECHNIQUE
8.6.2.1 MICROBIAL CULTURE TECHNIQUES/DIRECT ASSAY
8.6.2.2 POLYMERASE CHAIN REACTION
8.6.2.3 ELISA
8.6.2.4 DNA STAINING/INDIRECT ASSAY
8.6.2.5 ENZYMATIC METHODS
8.6.2.6 OTHERS
8.7 OTHERS
8.7.1 BY CAUSATIVE AGENT
8.7.1.1 MYCOPLASMA PNEUMONIAE
8.7.1.2 MYCOPLASMA HOMINIS
8.7.1.3 UREAPLASMA UREALYTICUM
8.7.1.4 MYCOPLASMA GENITALIUM
8.7.1.5 OTHERS
8.7.2 BY TECHNIQUE
8.7.2.1 MICROBIAL CULTURE TECHNIQUES/DIRECT ASSAY
8.7.2.2 POLYMERASE CHAIN REACTION
8.7.2.3 ELISA
8.7.2.4 DNA STAINING/INDIRECT ASSAY
8.7.2.5 ENZYMATIC METHODS
8.7.2.6 OTHERS
9 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 DIAGNOSTIC LABORATORIES
9.4 OTHERS
10 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET, BY GEOGRAPHY
10.1 NORTH AMERICA
10.1.1 U.S.
10.1.2 CANADA
10.1.3 MEXICO
11 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET, COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
12 COMPANY PROFILE
12.1 BIO-RAD LABORATORIES, INC.
12.1.1 COMPANY SNAPSHOT
12.1.2 REVENUE ANALYSIS
12.1.3 COMPANY SHARE ANALYSIS
12.1.4 PRODUCT PORTFOLIO
12.1.5 RECENT DEVELOPMENTS
12.2 MERCK KGAA
12.2.1 COMPANY SNAPSHOT
12.2.2 REVENUE ANALYSIS
12.2.3 COMPANY SHARE ANALYSIS
12.2.4 PRODUCT PORTFOLIO
12.2.5 RECENT DEVELOPMENT
12.3 BIOMeRIEUX SA
12.3.1 COMPANY SNAPSHOT
12.3.2 REVENUE ANALYSIS
12.3.3 COMPANY SHARE ANALYSIS
12.3.4 PRODUCT PORTFOLIO
12.3.5 RECENT DEVELOPMENTS
12.4 SARTORIUS AG
12.4.1 COMPANY SNAPSHOT
12.4.2 REVENUE ANALYSIS
12.4.3 COMPANY SHARE ANALYSIS
12.4.4 PRODUCT PORTFOLIO
12.4.5 RECENT DEVELOPMENTS
12.5 AB ANALITICA SRL
12.5.1 COMPANY SNAPSHOT
12.5.2 PRODUCT PORTFOLIO
12.5.3 RECENT DEVELOPMENTS
12.6 AGILENT TECHNOLOGIES, INC.
12.6.1 COMPANY SNAPSHOT
12.6.2 REVENUE ANALYSIS
12.6.3 PRODUCT PORTFOLIO
12.6.4 RECENT DEVELOPMENTS
?
12.7 ELITECHGROUP
12.7.1 COMPANY SNAPSHOT
12.7.2 PRODUCT PORTFOLIO
12.7.3 RECENT DEVELOPMENTS
12.8 GOLD STANDARD DIAGNOSTICS
12.8.1 COMPANY SNAPSHOT
12.8.2 PRODUCT PORTFOLIO
12.8.3 RECENT DEVELOPMENTS
12.9 LIOFILCHEM SRL
12.9.1 COMPANY SNAPSHOT
12.9.2 PRODUCT PORTFOLIO
12.9.3 RECENT DEVELOPMENTS
12.10 LONZA
12.10.1 COMPANY SNAPSHOT
12.10.2 REVENUE ANALYSIS
12.10.3 PRODUCT PORTFOLIO
12.10.4 RECENT DEVELOPMENTS
12.11 OPERON
12.11.1 COMPANY SNAPSHOT
12.11.2 PRODUCT PORTFOLIO
12.11.3 RECENT DEVELOPMENTS
12.12 OSANG HEALTHCARE
12.12.1 COMPANY SNAPSHOT
12.12.2 PRODUCT PORTFOLIO
12.12.3 RECENT DEVELOPMENT
12.13 PROMOCELL GMBH
12.13.1 COMPANY SNAPSHOT
12.13.2 PRODUCT PORTFOLIO
12.13.3 RECENT DEVELOPMENTS
12.14 F. HOFFMANN-LA ROCHE LTD
12.14.1 COMPANY SNAPSHOT
12.14.2 REVENEUE ANALYSIS
12.14.3 PRODUCT PORTFOLIO
12.14.4 RECENT DEVELOPMENTS
12.15 SACACE BIOTECHNOLOGIES SRL
12.15.1 COMPANY SNAPSHOT
12.15.2 PRODUCT PORTFOLIO
12.15.3 RECENT DEVELOPMENT
?
12.16 SEEGENE INC. (2018)
12.16.1 COMPANY SNAPSHOT
12.16.2 REVENUE ANALYSIS
12.16.3 PRODUCT PORTFOLIO
12.16.4 RECENT DEVELOPMENTS
12.17 THERMO FISHER SCIENTIFIC INC.
12.17.1 COMPANY SNAPSHOT
12.17.2 REVENUE ANALYSIS
12.17.3 PRODUCT PORTFOLIO
12.17.4 RECENT DEVELOPMENT
12.18 ZEAKON DIAGNOSTICS
12.18.1 COMPANY SNAPSHOT
12.18.2 PRODUCT PORTFOLIO
12.18.3 RECENT DEVELOPMENT
13 SWOT AND DBMR ANALYSIS
14 CONCLUSION:
15 QUESTIONNAIRE
16 RELATED REPORTS